Literature DB >> 9655022

Prevention and treatment considerations in patients with drug-induced gingival enlargement.

E E Hall1.   

Abstract

Drug-induced gingival overgrowth is an iatrogenic disease caused by the use of phenytoin, cyclosporine, nifedipine, and other medications in the susceptible patient. The gingival overgrowth can be due to three causes: noninflammatory, hyperplastic reaction to the medication; chronic inflammatory hyperplasia; or a combined enlargement due to chronic inflammation and drug-induced hyperplasia. Drug-induced gingival enlargement can be minimized, but not prevented, by elimination of local irritants, meticulous oral hygiene, and regular periodontal recall. If gingival enlargement interferes with function, speech, esthetics, or oral hygiene, tissue reduction can be accomplished by gingivectomy or a flap procedure. Gingival enlargement may recur, especially in the patient with poor oral hygiene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9655022

Source DB:  PubMed          Journal:  Curr Opin Periodontol        ISSN: 1065-626X


  4 in total

1.  Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression.

Authors:  Samuel A Black; Philip C Trackman
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

Review 2.  Pathologic crossroads: cardio-vascular diseases, periodontal diseases and calcium antagonists.

Authors:  H Balan; E Popescu; G Angelescu
Journal:  J Med Life       Date:  2011-02-25

Review 3.  Cyclosporine A: Novel concepts in its role in drug-induced gingival overgrowth.

Authors:  Deepa Ponnaiyan; Visakan Jegadeesan
Journal:  Dent Res J (Isfahan)       Date:  2015 Nov-Dec

4.  Effect of periodontal treatment in renal transplant recipients.

Authors:  Ana Pejcic; Vidojko Djordjevic; Draginja Kojovic; Vesna Zivkovic; Ivan Minic; Dimitrije Mirkovic; Mariola Stojanovic
Journal:  Med Princ Pract       Date:  2013-12-20       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.